Skip to main content
Client Work

Theratechnologies Inc. establishes a US $50 million at-the-market facility

Reading Time 1 minute read Subscribe




Theratechnologies, a biopharmaceutical company focused on the development and commercialization of innovative therapies, established an at-the-market ("ATM") equity program allowing Theratechnologies to issue and sell up to US $50 million common shares from treasury (the "Common Shares") to the public at the Company's sole discretion and at the prevailing market price. Sales of the Common Shares under the ATM program will be made pursuant to the terms of a sales agreement dated July 23, 2021 with Cantor Fitzgerald & Co.

All Common Shares sold pursuant to the ATM will be sold through the Nasdaq Capital Market or another marketplace upon which the Common Shares are listed, quoted or otherwise traded in the United States, at the prevailing market price at the time of sale.

Fasken, with a team comprised of Jean-Pierre Chamberland and Oleg Stratiev acted as legal counsel to Theratechnologies in connection with this offering.


  • Québec



    Receive email updates from our team